The continuing correction in the biotechnology market is the main reason for a fall of 23.3% in the ...
The continuing correction in the biotechnology market is the main reason for a fall of 23.3% in the NAV per share of the International Biotechnology Trust (IBT) over the six months to 28 February 2002, according to managers Schroder Venture Life Sciences (SVLS). This compares with a fall in the Nasdaq Biotechnology Index of 13% in sterling terms and a fall of Bloomberg UK Biotechnology Index of 29.4% during the same period. SVLS said a further cause of underperformance has been writedowns in the value of holdings it inherited after becoming the manager of the trust last year.
‘Important to have an anchor’
Lack of innovation for solutions
Some 2,000 consumers affected
Achievements, charity work and other happy snippets